Novo’s Obesity Pill Hits Shelves as Comeback Medicine for Battered Stock

Novo NordiskNVO

is fighting to reclaim control of its narrative. The drugmaker is betting on America’s first GLP-1 obesity pill to restore investor confidence after its worst year in decades. Entering 2026 under pressure from pricing battles, leadership churn, and rising competition from Eli LillyLLY

, the company is rolling out an oral Wegovy priced from $149/mo to widen access and push back against cheap copycats.

• Trial data shows the highest Wegovy pill dose drove 16.6% weight loss over 64 weeks, beating Lilly’s oral orforglipron, which showed 12.4% weight loss over 72 weeks.
• The starter dose is already available in 70K+ US pharmacies, including CVSCVS
  and CostcoCOST
  , plus Ro and WW InternationalWW
  , with higher doses arriving this week.

The clock’s ticking: Sydbank analyst Søren Løntoft Hansen believes Novo is in a “must-win” moment in the US, noting the situation seems like a “show-me case” for skeptical investors. Patent expirations abroad and pressure for Most Favored Nation pricing threaten revenue just as competition from Lilly heats up. With Goldman Sachs seeing oral GLP-1s grabbing 24% of the 2030 market, Novo can’t afford to miss again.